Since the FDA's 2014 approval of omalizumab for the treatment of CSU in adults and adolescents (aged ≥12 years) who remain symptomatic after H1-antihistamine therapy, research has shifted toward investigating topics such as anti-IgE, pruritus, and IgE receptors. This evidence concerns the gene IGHE and Pruritus.